Guided Therapeutics (GTHP) Payables (2010 - 2025)

Guided Therapeutics' Payables history runs 16 years deep, the most recent figure standing at $2.5 million for Q4 2025.

• In Q4 2025, Payables rose 12.9% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $2.5 million (up 12.9% YoY), while the FY2025 annual figure was $2.5 million, up 12.9% from the prior year.
• Payables came in at $2.5 million for Q4 2025 at Guided Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $2.8 million in Q3 2025 to a low of $51770.0 in Q1 2023.
• A 5-year average of $2.0 million and a median of $2.2 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables slumped 97.92% in 2023 and soared 3662.8% in 2024, its largest moves.
• Guided Therapeutics' Payables stood at $135000.0 in 2021, then soared by 1561.16% to $2.2 million in 2022, then slipped by 8.59% to $2.0 million in 2023, then climbed by 8.93% to $2.2 million in 2024, then rose by 12.9% to $2.5 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $2.5 million, $2.8 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison